NCT04089189 2026-01-28
SABRINA
Impact Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
11 trialsNCT06617923 2025-10-27
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05391048 2025-09-16
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT07120451 2025-08-13
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Fudan University
Phase 2 Not yet recruiting
NCT07030439 2025-06-22
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Impact Therapeutics, Inc.
Phase 1 Completed
NCT07019194 2025-06-13
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT04434482 2024-09-19
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
Phase 1/2 Completed
NCT04351165 2021-08-24
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
Impact Therapeutics, Inc.
Phase 1 Completed
NCT04584515 2021-08-24
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
Impact Therapeutics, Inc.
Phase 1 Completed
NCT03508011 2021-03-30
A Study of IMP4297 in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
Phase 1 Completed
NCT04057729 2020-03-30
IMP4297 Food Effect Trial in Healthy Volunteers
Impact Therapeutics, Inc.
Phase 1 Completed